Together these results indicate that fisetin inhibits cancer-cell proliferation by inducing DNA damage via RFXAP/KDM4A-dependent demethylation of histone H3K36, which might be a novel therapeutic target for PDAC. The gene discussed is KDM4A; the disease is cancer.